May 30, 2019
Sysmex Inostics OncoBEAM(TM)-EGFR Digital PCR Liquid Biopsy Demonstrates Two-fold Higher Detection of p.T790M Mutations in 183 NSCLC Patients in Comparison Study
May 29, 2019
Sihuan Pharm Obtained Phase I to III Clinical Trial Approval for the Third Generation of EGFR Inhibitor XZP-5809
May 28, 2019
Bio-Techne's New Exosome-Based Liquid Biopsies Helping To Advance Personalized Care In Lung Cancer Diagnostics
May 10, 2019
Mylan Expands Oncology Portfolio with Launch of Generic Tarceva® Tablets
Mar 29, 2019
Black Diamond Therapeutics Presents Data From its Program Targeting Oncogenic Allosteric Mutations in EGFR for Glioblastoma as Late Breaker at the American Association for Cancer Research (AACR) Annual Meeting
Mar 21, 2019
Kanazawa University Research: Origin of Resistance to Lung-cancer Drug Discovered
Feb 05, 2019
Taiho Pharmaceutical and Cullinan Oncology Establish Collaboration to Develop TAS6417, Novel EGFR Tyrosine Kinase Inhibitor
Nov 15, 2018
Patients Launch New Study to Shed Light on EGFR-Positive Lung Cancers
Sep 28, 2018
Sysmex Inostics Announces Launch of OncoBEAMTM EGFR Kit v2 (RUO) in Europe and Asia
Sep 26, 2018
Global survey reveals that physicians need more information to assess the impact of treatment sequencing on patient survival in EGFR mutation-positive NSCLC
Sep 26, 2018
Blueprint Medicines Announces Proof-of-Concept Data Showing Combination of BLU-667 and Osimertinib Overcame Treatment Resistance in Two Patients with EGFR-Mutant, Non-Small Cell Lung Cancer and an Acquired RET Fusion
Sep 24, 2018
Okayama University Research: Insights Into Mechanisms Governing the Resistance to the Anti-Cancer Medication Cetuximab
Aug 29, 2018
The Bonnie J. Addario Lung Cancer Foundation Joins Forces with Patient Advocate Group to Advance Care for People with EGFR-Positive Lung Cancer
Aug 16, 2018
Sirnaomics Oncology IND Receives Green Light from US FDA to Initiate Study for Treatment of Cholangiocarcinoma
Aug 07, 2018
Seattle Children's Targets Solid Tumors in New CAR T-Cell Immunotherapy Trial
May 31, 2018
Benitec Biopharma reports financial results for the 2018 fiscal third quarter and provides operational update
Apr 24, 2018
ASX/NASDAQ Announcement
Apr 18, 2018
US FDA Approves TAGRISSO® (osimertinib) As 1st-Line Treatment For EGFR-Mutated Non-Small Cell Lung Cancer
Apr 18, 2018
Roche expands indication for cobas® EGFR Mutation Test v2 as a companion diagnostic with TAGRISSO®
Apr 16, 2018
Head and Neck Cancer Drugs Market Size Worth $1.41 Billion by 2022: Grand View Research, Inc.